Signal from the log
Solstice Oncology
225 M$ · Series A · United States · Biotech
Solstice Oncology développe le porustobart, un anticorps anti CTLA-4 de deuxième génération dont Harbour BioMed lui a cédé les droits hors Grande Chine en février 2026. Il est testé avant la chirurgie dans le cancer du côlon MSS, la forme majoritaire, que l'immunothérapie n'atteint pas.
Verified
Announced on , logged by the watch of 9 September 2026.
- Operation
- Funding round
- Announced amount
- 225 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by RA Capital Management , with Canaan Partners , Forbion
Provenance
Logged on 9 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.